Skip to content
To the full analysis

Sanara MedTech Stock: Fair Value

SMTI
$32.67Closing price of 19 Nov 2026MEQIRI Score 61 out of 100

The fair value of Sanara MedTech under our model is $36.27, the price is 10% below.

The fair value is an estimate from our model, not a price target.

Daily figure as of 20 Nov 2026

Valuation Signal

Fairly valued
Price
$32.67
Fair value
$36.27
Gap to fair value
−10%

In our model the price counts as cheap below $25.91 and expensive above $60.46 (uncertainty high, based on the price swings of the past year).

Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $29.75, at 7.8% it would be $46.10.

Where the Number Comes From

Earnings × 33.8
no data
Cash-flow model
$36.27
Fair value (model)
$36.27

From the cash-flow model alone; without earnings there is no industry value.

Ten-year cash-flow model from smoothed free cash flow and its past growth until it reaches 3.8%. Discounted at 8.8% (floor: government bond yield 3.8% plus 5 percentage points, since beta 0.87 times the risk premium would give less); no analyst estimates were available.

Calculate with your own assumptions

The Calculation Step by Step

With these figures the cash flow model arrives at $36.27 per share: free cash flow for the next ten years, each year discounted to today at 8.8%, plus the terminal value for the years after. The table explains the calculation; it is not a recommendation.

Calculation as a table
YearFree cash flowSourceDiscount factorPresent value (discounted at 8.8%)
2026$7.44Mextrapolated at 46.5%0.9189$6.84M
2027$9.95Mextrapolated at 33.7%0.8443$8.4M
2028$12.41Mextrapolated at 24.7%0.7758$9.63M
2029$14.71Mextrapolated at 18.5%0.7129$10.48M
2030$16.78Mextrapolated at 14.1%0.6550$10.99M
2031$18.62Mextrapolated at 11.0%0.6019$11.21M
2032$20.27Mextrapolated at 8.9%0.5530$11.21M
2033$21.76Mextrapolated at 7.3%0.5082$11.06M
2034$23.13Mextrapolated at 6.3%0.4669$10.8M
2035$24.41Mextrapolated at 5.6%0.4291$10.47M
StepValue
Sum of present values (ten years)$101.09M
Terminal value: cash flow 2035 × (1 + 3.8%) / (8.8% − 3.8%)$506.95M
Present value of terminal value (× 0.4291)$217.51M
Equity value (sum plus present value of terminal value)$318.61M
Shares (diluted)8.78M
Value per share (equity value divided by shares)$36.27
Fair value (from the cash flow model alone)$36.27

The model uses free cash flow after interest, which belongs to shareholders, discounted at the cost of equity. Net debt is therefore not deducted again.

Data and Required Disclosures

  • ; time horizon around 12 months
  • Rated Neutral since 7 Nov 2026; valuation signal Fairly valued since 17 Nov 2026
  • Price: closing price of 19 Nov 2026
  • Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2025. MEQIRI calculates the score and fair value itself every night.
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.